# Accro Bioscience Announces IND Clearance from NMPA for Phase II/III Clinical Trial of AC-201, a Highly Selective TYK2/JAK1 Inhibitor for the Treatment of Non-Segmental Vitiligo

- Link: https://www.thailand-business-news.com/pr-news/accro-bioscience-announces-ind-clearance-from-nmpa-for-phase-ii-iii-clinical-trial-of-ac-201-a-highly-selective-tyk2-jak1-inhibitor-for-the-treatment-of-non-segmental-vitiligo
- Published: 2026-09-08T19:20:00+07:00
- Author: PR Newswire

NEW YORK and SUZHOU, China, Sept. 8, 2026 /PRNewswire/ — Accro Bioscience (Suzhou)
Limited ("Accro") today announced that Shanghai Fosun Pharmaceutical Industrial 
Development Company Limited ("Fosun Pharma Industrial"), a subsidiary of its partner
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma"), has received approval
from China’s National Medical Products Administration (NMPA) to conduct a Phase 
II/III adaptive seamless design clinical trial of AC-201 tablets (Fosun development
code: FXS5626) for the treatment of non-segmental vitiligo. Fosun Pharma Industrial
plans to initiate the relevant clinical trial for this indication in mainland China
once the necessary conditions are met.

**About AC-201**

AC-201 is a novel, highly selective and potent oral small-molecule inhibitor of 
TYK2/JAK1 that binds to the pseudo kinase domain (JH2) of TYK2/JAK1, with minimal
effect on the JAK2/JAK2 signaling pathway. It is currently being developed to treat
immune mediated inflammatory diseases.

**About Accro Bioscience**

Accro Bioscience (Suzhou) Limited is a clinical-stage biotechnology company pioneering
the discovery, development and commercialization of novel therapeutics for inflammatory
and autoimmune diseases, by targeting molecular mechanisms of regulatory cell death.
The company’s robust pipeline of first- and best-in-class compounds offers the potential
for innovative, paradigm-shifting therapies.

**About Fosun Pharma **

Founded in 1994, Fosun Pharma (stock code: 600196.SH; 02196.HK) is an innovation-
driven global pharmaceutical and healthcare group. With the mission of Better Health
for Families Worldwide, we focus on developing innovative medicines, medical technologies
and diagnostics as well as delivering healthcare services. Through our business 
partner Sinopharm Group, we have also established pharmaceutical distribution network,
built a comprehensive pharmaceutical and healthcare ecosystem.

Fosun Pharma is dedicated to innovation and globalization. The company has established
a global R&D innovation system targeting at unmet medical needs. Our strategic focus
is on key therapeutic areas including oncology, immunology and inflammation, neurodegenerative
diseases, and selected cardiometabolic diseases and rare diseases. This approach
enables the development of high valued competitive pipelines and comprehensive healthcare
solutions. Meanwhile, Fosun Pharma has consolidated its core technical platforms
including but not limited to antibodies and antibody-drug conjugates (ADC), small
molecules and cell therapy. Additionally, we also actively advance cutting-edge 
therapeutic modalities such as radiopharmaceuticals and small nucleic acids. These
efforts have strengthened our early-stage innovative portfolios and accelerated 
the transformation of scientific discoveries to drug development. Our innovative
products are now available in more than 90 countries and regions worldwide, including
major markets across China, the United States, Europe, Africa, India and Southeast
Asia.

Looking ahead, guided by the strategy of "Innovation Driven, Deep Globalization,
and AI Embracement", Fosun Pharma remains committed to its core values: Care for
life, Continuous innovation, Pursuit of excellence and Sustainable partnership. 
We strive to become a leading global healthcare innovation integrator, ensuring 
that the benefits of medical innovation reach more patients worldwide, and contribute
to safeguarding human health.

---

  |  This article was produced by Cision PR Newswire, our trusted news partner. The views expressed and the content presented here are solely those of the author and may not fully reflect the opinions of Thailand Business News. |

---

 
**Read the original article :** [Accro Bioscience Announces IND Clearance from NMPA for Phase II/III Clinical Trial of AC-201, a Highly Selective TYK2/JAK1 Inhibitor for the Treatment of Non-Segmental Vitiligo ](http://www.prnasia.com/story/archive/5042378_CN42378_0?rand=184833)